Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 14 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer - after two or more therapies	Rivoceranib (Apatinib; YN968D1)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2020	View \| Download
Trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma – third-line	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2021	View \| Download
Trifluridine and Tipiracil for Metastatic Gastric Cancer – third line and above	Lonsurf; TAS-102 (fixed dose combination: Trifluridine; Tipiracil hydrochloride)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2018	View \| Download
Zolbetuximab for previously untreated advanced gastric or gastro-oesophageal junction adenocarcinoma	Zolbetuximab (IMAB362)	Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2022	View \| Download